Literature DB >> 17624659

The role of erythropoietin in central and peripheral nerve injury.

Marios G Lykissas1, Anastasios V Korompilias, Marios D Vekris, Grigorios I Mitsionis, Ekaterini Sakellariou, Alexandros E Beris.   

Abstract

Erythropoietin (Epo) is a cytokine which controls red cell production. Apart from the red cell surface, erythropoietin's receptor (Epo-R) is also expressed in a large variety of normal tissues. Erythropoietin, as well as its receptor, is present in the central and peripheral nervous system. As erythropoietin having direct and indirect effect on nerve cells, enhances antioxidotic enzyme production, antagonizes glutamate's cytotoxic action, metabolizes free radicals, normalizes cerebral blood flow, affects neurotransmitters release and stimulates neoangiogenesis. After injury of the central as well as the peripheral nervous system, Epo presents an anti-apoptotic action. In combination with its anti-apoptotic effect, Epo, by reducing the inflammatory response plays a crucial role in neuroprotection in many types of injury in the central and the peripheral nervous system. Epo's administration contributes to the recovery of mechanical allodynia and may be effective in peripheral nerve regeneration after neurorrhaphy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624659     DOI: 10.1016/j.clineuro.2007.05.013

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  18 in total

1.  The effects of potential neuroprotective agents on rat facial function recovery following facial nerve injury.

Authors:  Kalpesh T Vakharia; Robin W Lindsay; Christopher Knox; Colin Edwards; Doug Henstrom; Julie Weinberg; Tessa A Hadlock; James T Heaton
Journal:  Otolaryngol Head Neck Surg       Date:  2011-01       Impact factor: 3.497

2.  Use of Erythropoietin as adjuvant therapy in nerve reconstruction.

Authors:  J A Lohmeyer; E Essmann; S J Richerson; C Hagel; J T Egana; A Condurache; P Ganske; K Schulz; P Mailänder; H G Machens
Journal:  Langenbecks Arch Surg       Date:  2008-02-26       Impact factor: 3.445

3.  Erythropoietin attenuates advanced glycation endproducts-induced toxicity of Schwann cells in vitro.

Authors:  Ting Yu; Lei Li; Tianhua Chen; Zhen Liu; Huaxiang Liu; Zhenzhong Li
Journal:  Neurochem Res       Date:  2015-01-14       Impact factor: 3.996

4.  Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.

Authors:  Edward Litton; Peter Latham; Julia Inman; Jingjing Luo; Peter Allan
Journal:  Intensive Care Med       Date:  2019-07-11       Impact factor: 17.440

Review 5.  Role of innate inflammation in traumatic brain injury.

Authors:  Sandrine Bourgeois-Tardif; Louis De Beaumont; José Carlos Rivera; Sylvain Chemtob; Alexander G Weil
Journal:  Neurol Sci       Date:  2021-01-19       Impact factor: 3.307

Review 6.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 7.  Raves and risks for erythropoietin.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

Review 8.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

Review 9.  Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li; Yan Chen Shang
Journal:  Prog Neurobiol       Date:  2008-03-04       Impact factor: 11.685

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.